Lung cancer (Amsterdam, Netherlands) · 2026
Phase II study of ramucirumab plus erlotinib for treatment-naïve patients with EGFR-mutant non-squamous non-small cell lung cancer and pleural effusion (RELAY-Effusion).
СтатьяКлиническое исследование II фазыМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kaneda Hiroyasu, Tachihara Motoko, Toi Yukihiro, Kuyama Shoichi, Ichihara Eiki, Fujisaka Yasuhito, Azuma Koichi, Kurata Takayasu, Kubo Akihito, Tanaka Hisashi, Yamada Tadaaki, Yokoyama Toshihide, Kato Takahide, Yamamoto Ken, Katakami Nobuyuki, Kawai Ryota, Yoshida Hisako, Shintani Ayumi, Sawa Kenji, Kawaguchi Tomoya
Аннотация
INTRODUCTION: Malignant pleural effusion (MPE) develops in approximately 30-40% of patients with non-small cell lung cancer (NSCLC), including those harboring epidermal growth factor receptor (EGFR) mutations, and is generally associated with reduced responsiveness to EGFR tyrosine kinase inhibitors. This study aimed to investigate the efficacy of ramucirumab in the context of MPE, which remains unexplored.
METHODS: In this single-arm, multicenter, phase II study, we enrolled treatment-naïve patients with EGFR-mutant NSCLC complicated by MPE. They received ramucirumab (10 mg/kg) every 2 weeks plus erlotinib (150 mg) daily until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were objective response rate (ORR), overall survival (OS), and safety.
RESULTS: Forty patients were enrolled between December 2021 and December 2023 (median follow-up, 29.5 months). The median PFS and OS were 12.9 (95% confidence interval [CI], 7.3-16.7) and 36.3 (95% CI: 28.5- not available [NA]) months, respectively, with a 12-month OS rate of 87.5% and ORR of 77.5% (95% CI, 61.5-89.2%). The median drainage-free survival was 33.0 months (95% CI: 26.0-NA). Treatment-related adverse events occurred in 85% of patients (grade 5 = 0%; grade 3 or 4 = 22.5%); the most common were acneiform dermatitis (60.0%), decreased appetite (30.0%), increased aspartate aminotransferase concentration (25.0%), paronychia (22.5%), hypertension (22.5%), proteinuria (22.5%), and anemia (22.5%).
CONCLUSIONS: Although the primary endpoint was not met, the combination provided durable control of MPE and was well tolerated, suggesting potential value in symptom-focused management of this high-risk subgroup.
CLINICAL TRIAL REGISTRATION: Japan Registry of Clinical Trials (jRCTs051210138).
METHODS: In this single-arm, multicenter, phase II study, we enrolled treatment-naïve patients with EGFR-mutant NSCLC complicated by MPE. They received ramucirumab (10 mg/kg) every 2 weeks plus erlotinib (150 mg) daily until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were objective response rate (ORR), overall survival (OS), and safety.
RESULTS: Forty patients were enrolled between December 2021 and December 2023 (median follow-up, 29.5 months). The median PFS and OS were 12.9 (95% confidence interval [CI], 7.3-16.7) and 36.3 (95% CI: 28.5- not available [NA]) months, respectively, with a 12-month OS rate of 87.5% and ORR of 77.5% (95% CI, 61.5-89.2%). The median drainage-free survival was 33.0 months (95% CI: 26.0-NA). Treatment-related adverse events occurred in 85% of patients (grade 5 = 0%; grade 3 or 4 = 22.5%); the most common were acneiform dermatitis (60.0%), decreased appetite (30.0%), increased aspartate aminotransferase concentration (25.0%), paronychia (22.5%), hypertension (22.5%), proteinuria (22.5%), and anemia (22.5%).
CONCLUSIONS: Although the primary endpoint was not met, the combination provided durable control of MPE and was well tolerated, suggesting potential value in symptom-focused management of this high-risk subgroup.
CLINICAL TRIAL REGISTRATION: Japan Registry of Clinical Trials (jRCTs051210138).